

**NUTRACEUTICALS:
DESIGNER FOODS III
GARLIC, SOY AND LICORICE**

Edited by

Paul A. Lachance, Ph.D., FACN

Professor and Chair
Department of Food Science
Rutgers - The State University
New Brunswick, New Jersey

**FOOD & NUTRITION PRESS, INC.
TRUMBULL, CONNECTICUT 06611 USA**

**NUTRACEUTICALS:
DESIGNER FOODS III
GARLIC, SOY AND LICORICE**

F N P PUBLICATIONS IN FOOD SCIENCE AND NUTRITION

Books

NUTRACEUTICALS: DESIGNER FOODS III, P.A. Lachance
 DESCRIPTIVE SENSORY ANALYSIS IN PRACTICE, M.C. Gacula, Jr.
 APPETITE FOR LIFE: AN AUTOBIOGRAPHY, S.A. Goldblith
 HACCP: MICROBIOLOGICAL SAFETY OF MEAT, J.J. Sheridan *et al.*
 OF MICROBES AND MOLECULES: FOOD TECHNOLOGY AT M.I.T., S.A. Goldblith
 MEAT PRESERVATION: PREVENTING LOSSES AND ASSURING SAFETY,
 R.G. Cassens
 S.C. PRESCOTT, PIONEER FOOD TECHNOLOGIST, S.A. Goldblith
 FOOD CONCEPTS AND PRODUCTS: JUST-IN-TIME DEVELOPMENT, H.R. Moskowitz
 MICROWAVE FOODS: NEW PRODUCT DEVELOPMENT, R.V. Decareau
 DESIGN AND ANALYSIS OF SENSORY OPTIMIZATION, M.C. Gacula, Jr.
 NUTRIENT ADDITIONS TO FOOD, J.C. Bauernfeind and P.A. Lachance
 NITRITE-CURED MEAT, R.G. Cassens
 POTENTIAL FOR NUTRITIONAL MODULATION OF AGING, D.K. Ingram *et al.*
 CONTROLLED/MODIFIED ATMOSPHERE/VACUUM PACKAGING, A.L. Brody
 NUTRITIONAL STATUS ASSESSMENT OF THE INDIVIDUAL, G.E. Livingston
 QUALITY ASSURANCE OF FOODS, J.E. Stauffer
 THE SCIENCE OF MEAT AND MEAT PRODUCTS, 3RD ED., J.F. Price and
 B.S. Schweigert
 HANDBOOK OF FOOD COLORANT PATENTS, F.J. Francis
 ROLE OF CHEMISTRY IN PROCESSED FOODS, O.R. Fennema *et al.*
 NEW DIRECTIONS FOR PRODUCT TESTING OF FOODS, H.R. Moskowitz
 ENVIRONMENTAL ASPECTS OF CANCER: ROLE OF FOODS, E.L. Wynder *et al.*
 FOOD PRODUCT DEVELOPMENT AND DIETARY GUIDELINES, G.E. Livingston,
 R.J. Moshly and C.M. Chang
 SHELF-LIFE DATING OF FOODS, T.P. Labuza
 ANTINUTRIENTS AND NATURAL TOXICANTS IN FOOD, R.L. Ory
 UTILIZATION OF PROTEIN RESOURCES, D.W. Stanley *et al.*
 POSTHARVEST BIOLOGY AND BIOTECHNOLOGY, H.O. Hultin and M. Milner

Journals

JOURNAL OF FOOD LIPIDS, F. Shahidi
 JOURNAL OF RAPID METHODS AND AUTOMATION IN MICROBIOLOGY,
 D.Y.C. Fung and M.C. Goldschmidt
 JOURNAL OF MUSCLE FOODS, N.G. Marriott, G.J. Flick, Jr. and J.R. Claus
 JOURNAL OF SENSORY STUDIES, M.C. Gacula, Jr.
 JOURNAL OF FOODSERVICE SYSTEMS, C.A. Sawyer
 JOURNAL OF FOOD BIOCHEMISTRY, N.F. Haard, H. Swaisgood and B. Wasserman
 JOURNAL OF FOOD PROCESS ENGINEERING, D.R. Heldman and R.P. Singh
 JOURNAL OF FOOD PROCESSING AND PRESERVATION, D.B. Lund
 JOURNAL OF FOOD QUALITY, J.J. Powers
 JOURNAL OF FOOD SAFETY, T.J. Montville and D.G. Hoover
 JOURNAL OF TEXTURE STUDIES, M.C. Bourne and M.A. Rao

Newsletters

MICROWAVES AND FOOD, R.V. Decareau
 FOOD INDUSTRY REPORT, G.C. Melson
 FOOD, NUTRITION AND HEALTH, P.A. Lachance and M.C. Fisher

**NUTRACEUTICALS:
DESIGNER FOODS III
GARLIC, SOY AND LICORICE**

Edited by

Paul A. Lachance, Ph.D., FACN

Professor and Chair
Department of Food Science
Rutgers - The State University
New Brunswick, New Jersey

**FOOD & NUTRITION PRESS, INC.
TRUMBULL, CONNECTICUT 06611 USA**

Copyright © 1997 by
FOOD & NUTRITION PRESS, INC.
6527 Main Street, POB 374
Trumbull, Connecticut 06611 USA

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

Library of Congress Catalog Card Number: 97-060572
ISBN: 0-917678-40-0

Printed in the United States of America

DEDICATION

This book is dedicated to the memory of Dr. Herbert F. Pierson Jr., born 7 August 1952 in Trenton, New Jersey, who earned degrees in biochemistry and pharmacognosy.

As a scientist in the Diet and Cancer Prevention Branch, National Cancer Institute, he was Project Leader of the novel initiative to fingerprint the cancer-preventing compounds found in food. With boundless enthusiasm and energy, in 1989, he coined the descriptor "Designer Foods" to not only recognize the role of phytochemicals in thwarting disease pathogenesis, but to stimulate the food and pharmaceutical industries to research and to market existing and new foods "designed" to benefit the health of humans.

He was very closely allied to the three "Designer Foods" short courses held at Rutgers. By the time of the third Designer Foods short course, he had resigned his position at NCI to establish his own consulting business "Preventive Nutrition Consultants" in Woodinville, WA. In addition, he became involved, along with his wife, with the continuing education of pharmacist in this emerging field of herbals and designer or functional foods, which in the USA are grouped as Nutraceuticals.

He fought valiantly with lymphoma but his Creator called him home 14 March 1996.

CONTRIBUTORS

- AWAZU, SHOJI, Department of Biopharmaceutics, Tokyo University of Pharmacy and Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan
- BEECHER, C., Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (m/c 781), University of Illinois at Chicago, Chicago, IL.
- BENNINK, MAURICE R., Departments of Medicine, and Food Science and Human Nutrition, Michigan State University, East Lansing, MI.
- BLAKELY SHIRLEY, A.R., Food and Drug Administration, Office of Policy, Planning and Strategic Initiatives (HFS-19), 200 C Street, SW, Washington, DC.
- BOEHM-WILCOX, CHRISTA, Department of Veterinary Pathology, University of Sydney, NSW 2006, Australia.
- BOLAÑOS-JIMENEZ, FRANCISCO, Unite de Pharmacologie Neuro-Immuno-Endocrinienne, Institut Pasteur, 28 rue du Dr. Roux, F75015 Paris, France.
- BOSNIC, MEIRA, Department of Veterinary Pathology, University of Sydney, NSW 2006, Australia.
- CLARK, JAMES P., Henkel Corporation, 5325 South 9th Avenue, LaGrange, IL.
- CONSTANTINOU, ANDREAS, Chemoprevention Program, Department of Surgical Oncology, University of Illinois, Chicago.
- DAVIS, DEVRA L., U.S. Department of Health and Human Services, Public Health Service, Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, DHHS/PHS, 330 C Street S.W., Room 2132, Washington, DC.
- DIMITROV, NIKOLAY V., Departments of Medicine, and Food Science and Human Nutrition, Michigan State University, East Lansing, MI.
- DUKE, JAMES, U.S. Department of Agriculture, Agricultural Research Service, Building 003, Room 227, 10300 Baltimore Avenue, Beltsville, MD.
- ERDMAN, JOHN W. JR., Division of Nutritional Sciences, University of Illinois, 451 Bevier Hall, 905 S. Goodwin, Urbana, IL.
- FILLION, GILLES M., Unite de Pharmacologie Neuro-Immuno-Endocrinienne, Institut Pasteur, 28 rue du Dr. Roux, F75015 Paris, France.
- FILLION, MARIE-PAULE, Unite de Pharmacologie Neuro-Immuno-Endocrinienne, Institut Pasteur, 28 rue du Dr. Roux, F75015 Paris, France.
- GEARY, RICHARD S., Department of Applied Chemistry and Chemical Engineering, Southwest Research Institute, San Antonio, TX.
- GRIMALDI, BRIGITTE, Unite de Pharmacologie, Neuro-Immuno-Endocrinienne, Institut Pasteur, 28 rue du Dr. Roux, F75015 Paris, France.

- GUHR, GERDA, Department of Food Science, Rutgers — The State University, New Brunswick, NJ.
- HARTMAN, THOMAS, G., Center For Advanced Food Technology, Cook College, Rutgers University, New Brunswick, NJ.
- HASLER, CLARE M. Director, Functional Foods for Health Program, Department of Food Science and Human Nutrition, 103 Agricultural Bioprocess Lab, 1302 West Pennsylvania Avenue, Urbana, IL.
- HATONO, SHUNSO, Wakunaga Pharmaceutical Co., Ltd., 1624 Shimokotachi, Koda-cho, Takata-gun, Hiroshima Pref. 739-11, Japan.
- HENLEY, E.C., Protein Technologies International Inc., Checkerboard Square, St. Louis, MO.
- HORIE, TOSHIHARU, Department of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263, Japan.
- JENKS, BELINDA H., Protein Technologies International Inc., Checkerboard Square, St. Louis, MO.
- KAMADA, TAKAATSU, The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, Japan 036.
- KANAZAWA, TAKEMICHI, The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, Japan 036.
- KATSUKI, HIROSHI, Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan.
- KODERA, YUKIHIRO, Wakunaga Pharmaceutical Co., Ltd., 1624 Shimokotachi, Koda-cho, Takata-gun, Hiroshima Pref. 739-11, Japan.
- KOJINRA, RYUSUKE, Philadelphia Biomedical Research Institute, 100 Ross and Royal Roads, King of Prussia, PA.
- KRISHNARAJ, RAJABATHER, Geriatric Medicine (787), University of Illinois at Chicago, Chicago, IL.
- LACHANCE, PAUL A., Department of Food Science, Rutgers — The State University, New Brunswick, NJ.
- LEWANDOWSKI, C., Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (m/c 781), University of Illinois at Chicago, Chicago, IL.
- MATSUURA, HIROMICHI, Institute for OTC Research, Wakunaga Pharmaceutical Co., Ltd., Hiroshima, Japan.
- MEHTA, RAJENDRA G., Chemoprevention Program, Department of Surgical Oncology, University of Illinois, Chicago.
- METOKI, HIROBUMI, Reimeikyo Rehabilitation Hospital, 30 Ikarigaseki-mura, Aomori, Japan 038-01.

- MILLER, MICHAEL A., Department of Applied Chemistry and Chemical Engineering, Southwest Research Institute, San Antonio, TX.
- MOON, RICHARD C., Chemoprevention Program, Department of Surgical Oncology, University of Illinois, Chicago.
- MORIGUCHI, TORU, Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan.
- NISHINO, HOYOKU, Cancer Prevention Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-, Japan.
- NISHIYAMA, NOBUYOSHI, Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan.
- NIXON, DANIEL W., Associate Director, Cancer Prevention and Control, Hollings Cancer Center and Folk Professor of Experimental Oncology, Medical University of South Carolina, Charleston, SC.
- OHNISHI, S. TSUYOSHI, Philadelphia Biomedical Research Institute, 100 Ross and Royal Roads, King of Prussia, PA.
- OIKE, YASABURO, Reimeikyo Rehabilitation Hospital, 30 Ikarigaseki-mura, Aomori, Japan 038-01.
- ONODERA, KOGO, The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, Japan 036.
- OSANAI, TOMOHIRO, The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, Japan 036.
- PIERSON, HERBERT F., (Deceased), Vice President for Research and Development, Preventive Nutrition Consultants, Inc., 19508 189TH Place NE, Woodinville, WA.
- PINTO, JOHN T., Clinical Nutrition Research Unit & Nutrition Research Laboratory, Department of Medicine, Memorial Sloan-Kettering Cancer Center & New York Hospital — Cornell Medical Center, New York, NY.
- REEVE, VIVIENNE E., Department of Veterinary Pathology, University of Sydney, NSW 2006, Australia.
- RIVLIN, RICHARD S., Clinical Nutrition Research Unit & Nutrition Research Laboratory, Department of Medicine, Memorial Sloan-Kettering Cancer Center & New York Hospital — Cornell Medical Center, New York, NY.
- ROSEN, ROBERT T., Center For Advanced Food Technology, Cook College, Rutgers University, New Brunswick, NJ.
- ROZINOVA, EMILIA, Department of Veterinary Pathology, University of Sydney, NSW 2006, Australia.
- SAITO, HIROSHI, Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan.
- SARHAN, HALA, Unite de Pharmacologie Neuro-Immuno-Endocrinienne, Institut Pasteur, 28 rue du Dr. Roux, F75015 Paris, France.

- SCHMEISSER, DALE D., Department of Nutrition and Medical Dietetics,
University of Illinois, Chicago, Chicago, IL
- SIEBERT, BRIAN D., CSIRO Division of Human Nutrition, Adelaide, SA,
Australia.
- STEELE, VERNON, Chemoprevention Branch, The National Cancer Institute,
Bethesda, MD.
- TESTA, LUCIA C.A., MacAndrews and Forbes Co., 3rd Street and Jefferson
Avenue, Camden, NJ.
- UEMURA, TSUGUMICHI, The Second Department of Internal Medicine,
Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori,
Japan 036.
- VORA, PETER S., MacAndrews and Forbes Co., 3rd Street and Jefferson
Avenue, Camden, NJ.
- WAGGLE, DOYLE H., Protein Technologies International Inc., Checkerboard
Square, St. Louis, MO.
- WARGOVICH, MICHAEL J., Section of Gastrointestinal Oncology and
Digestive Disease, University of Texas, M.D. Anderson Cancer Center,
Houston, TX.
- WEINBERG, DAVID S., Southern Research Institute, 2000 Ninth Avenue,
South, Birmingham, AL.
- ZHANG, YONGXIANG, Department of Chemical Pharmacology, Faculty of
Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-
Ku, Tokyo 113, Japan.
- ZHOU, JIN-R., Nutrition & Metabolism Laboratory, Beth Israel Deaconess
Medical Center, 194 Pilgrim Road, Boston, MA.

PREFACE

The term "Designer Foods" was the programmatic and funding term of the National Cancer Institute and can be briefly defined as the study of one or more phytochemical components(s) acting individually, additively or synergistically, usually as component(s) of whole food, that have the characteristic of providing protective, preventative and possibly curative roles in the pathogenesis of cancer and other chronic disease progressions. The observation of benefits may be based on the results of one or more epidemiological, *in vitro* and/or *in vivo* cellular, organ system or whole organism assays, and may include human clinical experiences and trials. Other terms have emerged to describe "designer foods." The University of Illinois has evolved a coordinated phytochemical research effort entitled "Functional Foods for Health." Dr. Stephen DeFelice of the Foundation for Innovative Medicine coined the term "Nutraceutical" to describe beneficial phytochemicals. This term has gained considerable acceptance because it is unique, concise and somewhat descriptive of the intended field of endeavor.

Rutgers held the first short course on Designer Foods in January 1990, and the second in March 1993, with the third being held 23-25 May 1994 at Georgetown University of which these are the proceedings.

In contrast to the field of Pharmacognosy and the discovery of drugs from natural products, nutraceutical research discovers substances that are considered a food or a part of a food and which provide health or even medical benefits. Such substances are invariably phytochemicals and may range from being isolated nutrients to other non-nutrient phytochemicals that act directly, or may exert biochemical activity directly, or by modulating genomic materials. Food, be it commodity, or herb, or spice, is any substance that is eaten or otherwise taken into the body (e.g., ostomy) to sustain psychological and physiological life, provide energy and promote the biochemical and physiological interactions that are nutrition. The substance of food is a vast array of chemicals of which a very small number are essential to life and are recognized and classified as nutrients. In contrast a vast array of food chemicals provide flavor, color and texture attributes, while others are key to the metabolism of the food (e.g., enzymes). Of the functions of food, nine are psychological and only three are physiological. Nutraceuticals are naturally-occurring and if determined to be beneficial could be biotechnologically-enhanced.

A paradigm I have evolved to give dimension to the breadth and potential of the implications of nutraceuticals is shown in Fig. P.1. There are four major components to the paradigm. First is the recognition that a major consideration in the risk of any disease developing is our genetic make-up revealed to some degree by our family history. Secondly, there is no question




FIG. P.1. PARADIGM OF METABOLIC PREVENTION ROLE FOR NUTRACEUTICALS

The paradigm utilizes concepts of phases in cancer induction recognizing that a genetic predisposition exists. In addition renewable cells are more prone to pathology. The predominate philosophy is treatment *after* recognition of the pathology at the high costs associated with high-tech-rescue medicine. Lifestyle practices, such as exposure to smoking and antioxidant dietary composition, can induce, accelerate or thwart partially or completely the initiation of the pathogenesis. Nutraceuticals function at the metabolic prevention level to block, inhibit or suppress promotion, thus thwarting pathogenesis and the cost of pathology and its consequences.

that our exposure to the environment, including smoking, and to various favorable and unfavorable diet components can be partially counterbalanced by our choice of lifestyle practices, such as consuming no less than five servings of fruit and vegetables per day and regular exercise. Thirdly, today's medical care system is devoted to the remediation of disease that is already pathological, and thus we experience a very costly practice of high-tech-rescue medicine. The fourth dimension encompasses the overlooked numerous metabolic steps in the transformation of normal cellular events into damaged events (e.g., oxidized or precancerous lesions), which nutraceuticals at the proper dose can block or suppress, or metabolically transform, thus setting the stage to prevent, or even revert pathology. The mechanisms of action of the various nutraceuticals may be one or several. For example, free radical scavenger and antioxidant

nutraceuticals can nullify damage by any number of biochemical mechanisms, but some also exert benefit by enhancing immune function. Table P.1 lists the broad classes of compounds that have nutraceutical activity, and there are very likely more classes of compounds that have nutraceutical activity. It is very likely there are many other nutraceutical components, as well as interactions, yet to be discovered.

TABLE P.1
PHYTOCHEMICALS: THE NEXT FRONTIER

Phytochemical Family	Food Sources
Allyl Sulfides	Onions, garlic, leeks, chives
Indoles	Cruciferous vegetables (broccoli, cabbage, kale, cauliflower)
Isoflavones	Soybeans (tofu, soy milk)
Isothiocyanates	Cruciferous vegetables
Phenolic Acids (ellagic acid, ferulic acid)	Tomatoes, citrus fruits, carrots, whole grains, nuts
Polyphenols	Green tea, grapes, wine
Saponins	Beans and legumes
Terpenes (perillyl alcohol, limonene)	Cherries, citrus fruit peel

A very conservative 1993 economic analysis of solely hospital care costs and the role that three nutrient antioxidants could exert on cardiovascular disease, breast cancer and cataracts is presented in Table P.2. It is common knowledge that billions of dollars are expended each year for hospital cost relating to breast, lung, stomach and other cancers, cardiovascular disease and cataracts. The study¹ considers the potential impact of only three antioxidants, namely vitamin C, vitamin E and beta carotene; the annual savings in hospital care costs alone would exceed 8 billion dollars. Expert public health physicians² believe that as much as 70% of disease is in fact preventable!

TABLE P.2
U.S. HOSPITALIZATION EXPENDITURES

	Total <u>Expenditures</u> (\$ Mil)	Percentage Preventable from Increased <u>Antioxidants</u> (Vits. C,E, Beta-Carotene)	Estimated Medicare Cost <u>Savings</u> (\$ Mil)	Estimated Total <u>Savings</u> (\$ Mil)
Cancer				
Breast	1,088.3	16	27.4	174.1
Lung	3,263.7	21	125.4	685.4
Stomach	538.0	30	43.6	161.4
Cardiovascular Disease	30,823.7	25	1,500.0	7,705.9
Cataracts	<u>98.5</u>	50	<u>7.1</u>	<u>49.3</u>
TOTAL	35,812.3		1,676.6	8,776.1 Annual

Source: Pracon Inc. Economic Analysis (1993)

The papers in this symposium were organized to reveal the existing and emerging knowledge of the nutraceuticals found in garlic, soy and licorice. The lead paper discusses the epidemiological evidence, and the papers following present and discuss chemical or biochemical evidence at the cellular level; and some clinical data are presented.

I'm indebted to the late Dr. Herbert Peirson, who first headed up the Designer Foods Program for the National Cancer Institute and later had the courage and foresight to start a consulting business in this area. His suggestions as to relevant investigators were invaluable, as was his assistance in gaining funding to support the symposium/short course. He served as co-chair of the meeting and these proceedings which I have chosen to dedicate to his memory. We in turn are indebted to the authors who provided succinct texts of their presentations to serve as a status summary of the current state of the available knowledge.

A major conclusion of the overall effort is that the science is very incomplete, but that the findings to date have great promise. The problem is that marketing persons are trying to capitalize on the "promise" of the existing knowledge, but often to a degree that the existing data cannot support. In the interim, the consumer needs to increase their intakes of conventional fruits and

vegetables and some cereal grain products, but otherwise should “beware” of the false and misleading promises.

REFERENCES

- ¹ Anon. 1993. The potential of antioxidant vitamins in reducing health care costs. Pracon Inc., Reston, VA. Commissioned by the Council for Responsible Nutrition, Washington, D.C.
- ² James F. Fries, C. Everett Koop — The health project. *The Sciences* (NYAS) 34(1):19, 1994.

PAUL A. LACHANCE
NEW BRUNSWICK, NEW JERSEY

CONTENTS

CHAPTER	PAGE
Section I. Perspectives	
1. PLANT FOODS IN DISEASE PREVENTION — STUDY OF PROCEDURE LESSONS FROM EASTERN VERSUS WESTERN DIET, <i>Devra L. Davis</i>	1
2. SAPONINS IN <i>ALLIUM</i> VEGETABLES, <i>C. Lewandowski and C. Beecher</i>	7
Section II. The Chemical and Biological Principles of Designer Foods	
3. OVERVIEW OF ANALYTICAL TECHNIQUES FOR THE FINGERPRINTING OF PHYTOCHEMICALS IN DESIGNER FOODS, <i>Robert T. Rosen and Thomas G. Hartman</i>	15
4. CHEMICAL EFFECTS OF PROCESSING AND FOOD PREPARATION ON CAROTENOIDS AND SOY AND GARLIC PHYTOCHEMICALS, <i>Jin-R. Zhou and John W. Erdman, Jr.</i>	23
5. PHYTOCHEMICALS: BIOCHEMICAL MARKERS OF INGESTION, ABSORPTION AND METABOLISM USING FLAXSEED AS A MODEL, <i>Clare M. Hasler</i>	39
6. RESEARCH APPROACHES TO SPECIAL PRECLINICAL SAFETY AND TOXICOLOGICAL EVALUATIONS, <i>Shirley A.R. Blakely</i>	45
Section III. Phytopharmacology of Garlic Food Forms	
7. PHYTOCHEMISTRY OF GARLIC HORTICULTURAL AND PROCESSING PROCEDURES, <i>Hiromichi Matsuura</i>	55

8.	INTERNATIONAL PHYTOTHERAPEUTIC USES OF GARLIC FOOD FORMS, <i>Rajabather Krishnaraj</i>	71
9.	LIPID SOLUBLE PHYTOCHEMICAL CONSTITUENTS IN GARLIC FOOD FORMS, <i>David S. Weinberg</i>	81
10.	CHEMICAL METHODS DEVELOPMENT FOR QUANTITATION OF PHYTOCHEMICALS IN AQUEOUS GARLIC EXTRACT, <i>Richard S. Geary and Michael A. Miller</i>	87
11.	DIETARY TOLERANCE/ABSORPTION/METABOLISM OF PHYTOCHEMICALS IN GARLIC, <i>Yukihiro Kodera</i>	95
12.	ANTIOXIDANT ACTIVITIES OF AGED GARLIC EXTRACTS AND CANCER CHEMOTHERAPY, <i>S. Tsuyoshi Ohnishi and Ryusuke Kojinra</i>	105
13.	IMPROVEMENT OF AGE-RELATED DETERIORATION OF LEARNING BEHAVIORS AND IMMUNE RESPONSES BY AGED GARLIC EXTRACT, <i>Yongxiang Zhang, Toru Moriguchi, Hiroshi Saito and Nobuyoshi Nishiyama</i>	117
14.	ANTIOXIDANTS IN GARLIC. II. PROTECTION OF HEART' MITOCHONDRIA BY GARLIC EXTRACT AND DIALLYL POLYSULFIDE FROM THE DOXORUBICIN-INDUCED LIPID PEROXIDATION, <i>Shoji Awazu and Toshiharu Horie</i>	131
15.	ROLE OF GARLIC IN DISEASE PREVENTION — PRECLINICAL MODELS, <i>Shunso Hatono and Michael J. Wargovich</i>	139
16.	EFFECTS OF AGED GARLIC EXTRACT ON RAT BRAIN NEURONS, <i>Hiroshi Saito, Toru Moriguchi, Yongxiang Zhang, Hiroshi Katsuki and Nobuyoshi Nishiyama</i>	153
17.	DIETARY AGED GARLIC EXTRACT INHIBITS SUPPRESSION OF CONTACT HYPERSENSITIVITY BY ULTRAVIOLET B (UVB, 280-320 NM) RADIATION OR CIS UROCANIC ACID, <i>Vivienne E. Reeve, Meira Bosnic, Emilia Rozinova and Christa Boehm-Wilcox</i>	163

18. GARLIC AND PREVENTION OF PROSTATE CANCER, <i>John T. Pinto and Richard S. Rivlin</i>	177
19. POTENTIAL INTERACTION OF AGED GARLIC EXTRACT WITH THE CENTRAL SEROTONERGIC FUNCTION: BIOCHEMICAL STUDIES, <i>Gilles M. Fillion, Marie-Paule Fillion, Francisco Bolaños-Jimenez, Hala Sarhan and Brigitte Grimaldi</i>	189
20. GARLIC AND SERUM CHOLESTEROL, <i>Dale D. Schmeisser</i> .	193
21. MODULATION OF ARACHIDONIC ACID METABOLISM BY GARLIC EXTRACTS, <i>Nikolay V. Dimitrov and Maurice R. Bennink</i>	199

Section IV. Phytopharmacology of Soy Food Forms

22. ISOLATED SOY PROTEIN TECHNOLOGY — POTENTIAL FOR NEW DEVELOPMENTS, <i>Belinda H. Jenks, Doyle H. Waggle and E.C. Henley</i>	203
23. ROLE OF SOY FOOD FORMS IN PREVENTION OF HUMAN VASCULAR DISEASE, <i>Takemichi Kanazawa, Tomohiro Osanai, Tsugumichi Uemura, Takaatsu Kamada, Kogo Onodera, Hirobumi Metoki and Yasaburo Oike</i>	219
24. COMMERCIAL PHYTOCHEMICALS FROM SOY, <i>James P. Clark</i>	237

Section V. Phytopharmacology of Licorice Food Forms

25. PHYTOCHEMISTRY OF LICORICE HORTICULTURAL AND PROCESSING PROCEDURES, <i>Peter S. Vora and Lucia C.A. Testa</i>	243
26. PHYTOCHEMICAL CONSTITUENTS IN LICORICE, <i>James Duke</i>	259

27. LICORICE: ABSORPTION, DISTRIBUTION, METABOLISM AND CANCER CHEMOPREVENTION, <i>Rajendra G. Mehta, Vernon Steele, Herbert Pierson, Andreas Constantinou and Richard C. Moon . . .</i>	265
28. CANCER PREVENTION BY LICORICE, <i>Hoyoku Nishino . . .</i>	279
29. CLINICAL EVALUATION AND SAFETY OF LICORICE- CONTAINING FORMULATIONS, <i>Herbert F. Pierson</i>	285

Section VI. Bridging the Gaps in Knowledge for Designer Food Applications

30. STUDIES OF PLANT FOODS FOR DISEASE PROTECTION, <i>Brian D. Siebert</i>	301
31. ONGOING AND FUTURE CLINICAL NUTRITION RESEARCH NEEDS, <i>Daniel W. Nixon</i>	305
32. ROLE OF PHYTOCHEMICALS IN CHRONIC DISEASE PREVENTION, <i>Gerda Guhr and Paul A. Lachance</i>	311

SECTION I
PERSPECTIVES

CHAPTER 1

**PLANT FOODS IN DISEASE PREVENTION — STUDY OF
PROCEDURE LESSONS FROM EASTERN VERSUS
WESTERN DIET**

DEVRA L. DAVIS

*U.S. Department of Health and Human Services
Public Health Service
Assistant Secretary for Health
Office of Disease Prevention and Health Promotion
DHHS/PHS
330 C Street, S.W., Room 2132
Washington, D.C. 20201*

ABSTRACT

A synopsis is presented of two publications concerning disease prevention associated with plant food constituents. Human breast cancer is increasing worldwide. Total lifetime exposure to estrogen is a risk factor; 16 alpha hydroxyestrone increases tumor growth. Indole-2-carbinol and genestein promote an alternate favorable pathway to 2-hydroxyestrone. Natural products are evidently sources of potent anticarcinogens but require research.

Some Clues about Plant Foods in Disease Prevention

These remarks introduce reprints of two recent papers pertinent to the subject of opportunities for disease prevention through plant foods. Before presenting these papers, I want to recapitulate the theory that some portion of breast cancer today may be due to avoidable exposures to some xenoestrogenic materials, and that other xenoestrogenic materials, which are natural products and plant foods, may help to prevent breast cancer. This work has been developed with H. Leon Bradlow, of Cornell Medical Center, Mary Wolff of Mt. Sinai Medical Center, and other colleagues who are part of the Breast Cancer Prevention Collaborative Research Group (BCPCRG). The BCPCRG is an informal network of clinical, toxicologic, and epidemiologic researchers who

work chiefly on the Internet and by Fax to exchange late-breaking developments pertinent to the identification of avoidable causes of breast cancer.

Breast Cancer

Though breast cancer mortality has recently fallen in younger white women, mortality and incidence have risen substantially for African American women of all ages and for all women over 65 in the U.S. and U.K. Worldwide patterns also reveal growing breast cancer incidence and mortality. Geographic and time trend analysis provide an especially intriguing part of the breast cancer puzzle, and bolster the notion that a substantial portion of breast cancer should be avoidable. Women and men in Japan and Asia have rates of new cases and deaths from breast cancer that are consistently about five times lower than those in other industrial countries. Breast cancer mortality for women ages 45 to 84 in 15 major industrial countries from 1968 to 1986, grouped into six major global regions, rose between 0.2 and 2% annually. While rates are highest in U.K. and U.S., the fastest rate of growth is evident in East Asia and Eastern Europe, two regions where mammographic screening cannot generally be conducted. Thus, breast cancer deaths in all countries appear to be on the rise, growing most in regions where improved diagnostic technology does not play a role.

For breast cancer, and possibly other hormonally mediated cancers, such as testicular, prostate, and endometrium, the common factor which links most known risk factors is total lifetime exposure to estrogen. Based on epidemiologic studies and on previous experimental research that found that many of the same materials which increase breast tumor development in animals are also estrogenic, we have recently hypothesized that some breast cancer cases are due to avoidable environmental exposures that increase estrogen levels and alter overall metabolism. We have termed these materials "xenoestrogens." They include some organochlorine pesticides, pharmaceuticals, fuels, plastics, and natural products — all of which have been found to affect the amounts and types of estrogen produced.

Experimental studies on the ability of a wide variety of materials to affect estrogen production have been conducted for more than two decades in several medical laboratories. For breast and other hormonally mediated cancers, agents which affect the body's natural levels of estrogen may thereby affect the risk of breast cancer. With respect to PCBs, a number of isomers are anti-estrogenic, while others are potent estrogens. The picture is complex and incomplete, but clearly indicates that a number of widely used compounds affect estrogen production and metabolism and other hormonally mediated biologic activities.

We have hypothesized that two competing enzyme systems can alter metabolism of the 18-carbon estradiol by contending for two mutually exclusive pathways. Pathway I inserts a hydroxyl (OH•) radical at the 2-carbon position and yields the catechol estrogen 2-hydroxyestrone (2-OHE₁), a weakly anti-estrogenic metabolite. Pathway II adds an OH• at the 16 position and yields 16 α -hydroxyestrone (16 α -OHE₁); this creates a fully potent metabolite which increases tumor growth, DNA damage and cell proliferation. While many of the synthetic materials identified as xenoestrogens to date promote the cell proliferative pathway, several natural products, such as indole-2-carbinol and genistein, appear to promote the beneficial pathway. Studies underway in laboratories across the country will clarify the relative role of these materials in helping reduce the risk of recurrence in women with breast cancer, as well as in reducing the risk of the disease overall. David Zava and others have recently speculated that genistein and related compounds may work by keying into estrogen receptors, and blocking its activation by more potent estradiol. In fact, most xenoestrogens identified to date are thousands of times less potent than the body's own estradiol. But, materials such as genistein can occur with circulating levels that are thousands of times higher than those of the body's own estradiol, especially in Asian women whose diets are rich in soy products.

Papers Published

The first paper¹ reviews in vitro and in vivo evidence that a number of common natural products function as potent anticarcinogens. The second paper² assesses patterns of cancer in farmers as clues to preventable causes of the disease.

Both papers^{1,2} present evidence that current patterns of cancer may be linked, in part, to avoidable exposures. We know that it is feasible to prevent cancer because the rates of the disease vary substantially, even within the industrial world. The rates of brain cancer, multiple myeloma, and breast cancer are all three to five times higher in the United States for males and females than in Japan. This variation in patterns between countries suggests that there are preventable factors.

Consider what is generally known about cancer. Genetics, which gets a lot of front-page coverage, explains, in some sense, all about cancer. But, only a small proportion of cancer is in fact inherited. Most cancer is acquired in a lifetime through interaction of normal genes with the environment, which obviously includes nutrition as a major component. We have to ask what in the environment interacts with the inherited genes that most people have to cause the development of cancer. Food, air, and water sustain life and are also critical components of the environment to which we are all exposed every day of our lives. This essential microenvironment contains both natural and synthetic carcinogens and anticarcinogens.

As to other major causes of cancer, smoking is the single most important preventable cause in industrial countries. Food is a very important factor, both in terms of preventing and causing cancer. Contamination with mycotoxins and fungal molds in the developing world is an important factor, which explains some of the high rates of esophageal, liver and stomach cancer that are endemic in parts of Asia and Africa.

Chemicals, as dusts and fumes, have been clearly characterized as important causes of cancer in highly exposed workers. Sexual practices are relevant to AIDS, but are also relevant to cervical cancer. Viruses, except for the AIDS virus, have not yet been identified as clear viral causes of human cancer, but have been implicated for stomach cancer, as well as cervix. And of course, radiation — both ionizing and non-ionizing — is important, as it can ionize cells and lead to direct mutations.

With my colleagues, David Hoel and Gregg Dinse, I published in 1994³ a relevant article in the *Journal of the American Medical Association*. We found that baby-boomer males had three times higher rates of cancer not related to smoking than we estimate occurred for their grandfathers. Many of the tumors that have occurred at greater rates in these men, also have occurred more often in farmers; the latter are reviewed in reference number 2. And baby-boomer females have a 50% higher rate of new cases of cancer compared to their grandmothers. We took away the smoking-related cancers to do this analysis, as we wanted to see whether causes other than smoking appeared to be operating.

Taken together with the theory of xenoestrogens, these three publications provide evidence that some segment of cancer is preventable. Variations in cancer rates may very well be linked to parts of the environment, including foods as protective factors and as sources of contaminants. We have to ask what we control as a society that will reduce the risk of cancer? We all recognize that food policy is a vital part of preventative public health programs. In the past, ketchup was proposed as a vegetable in the school lunch program. New guidelines have been developed that provide for more consumption of fruits and vegetables, less consumption of salt and animal fat. Other ways to effect positive food policy changes will include programs or subsidies that we can change. Thus, beef is now graded as to fat content. And subsidies could be developed to reward those who produce healthier produce. Rather than subsidize and stockpile butter, we could develop economic incentives to encourage the production of more healthful crops, such as soy, and to discourage tobacco, which could prove quite valuable in advancing public health.

The rationale for pursuing opportunities to prevent cancer and other diseases grows stronger day by day. New cases of cancer in young persons continue to increase for reasons that are unclear. And rates of deaths from cancer have increased in persons over 65. Along with other efforts to promote

health and prevent disease, the development of foods rich in anticarcinogens could play a critical role in ensuring that fewer cases of cancer occur in the first place.

REFERENCES

- ¹ Davis, D.L. and Babich, H. Natural Anticarcinogens and Mechanisms of Cancer. *In Handbook of Hazardous Materials*, (Corn, M., ed.) Baltimore. Academic Press, San Diego, 1993:463-474.
- ² Davis, D.L., Blair, A. and Hoel, D.G. Agricultural Exposures and Cancer Trends in Developed Countries. *Environmental Health Perspectives* 1992; 100:39-44.
- ³ Davis, D.L., Dinse, G.E. and Hoel, D.G. Decreasing Cardiovascular Disease and Increasing Cancer Among Whites in the United States From 1973 through 1987. *J Am. Med. Assoc.* 1994; 271:431-437.

SAPONINS IN *ALLIUM* VEGETABLES

C. LEWANDOWSKI and C. BEECHER

*Program for Collaborative Research in the Pharmaceutical Sciences
Department of Medicinal Chemistry and Pharmacognosy
College of Pharmacy (m/c 781)
University of Illinois at Chicago
Chicago, IL 60612*

ABSTRACT

The saponins of the genus Allium have been little explored either chemically or biologically, possibly because of the intense interest in the more obvious classes of Allium compounds, the thiols and flavonoids. This brief survey demonstrates the chemical complexity of Allium saponins in an attempt to direct researchers' attention to this little recognized class of dietary compounds.

INTRODUCTION

Allium species are among the most widely used of all of the flowering plants. Consider first that one or more members of this widespread genus are an integral component in almost every cuisine. As Table 2.1 shows, the most prominent members of the genus are recognized as foods by almost all of the races of man. A less commonly acknowledged, but almost as universal, fact is the use of these plants for a variety of medical conditions. In the United States this unacknowledged fact has developed into a large and lucrative but somewhat underground market. Though openly sold for "medical" uses, to the tune of millions of dollars per year, the Food and Drug Administration (FDA) has yet to sanction, or conduct a detailed investigation into the use of, any *Allium* product for any specific medical condition. This is unfortunate in view of the extensive peer-reviewed, yet highly variable, experimental/medical literature that surrounds these plants and the chemical compounds that they contain. In this brief review, we will examine in some detail the chemical, taxonomic and biological range of one of the minor classes of compounds that is found in these plants, namely, saponins. This class of compounds may hold the key to some of the medical claims and may explain the variability of the published results, since

different preparation protocols will either concentrate or remove them from the final product.

***Allium* Taxonomy**

The genus *Allium*, in the family Amaryllidaceae, is a genus of perennial herbs usually with bulbous rootstocks. Their leaves are simple and more-or-less linear. There are some 300 defined species, many of which are human dietary components (see Table 2.1). Some are horticulturally ornamental. Only a small portion of the known species have been chemically examined.

TABLE 2.1
COMMONLY CONSUMED *ALLIUM* SPECIES

Species	Common name
<i>Allium cepa</i>	Onion
<i>Allium sativum</i>	Garlic
<i>Allium ascalonium</i>	Shallot
<i>Allium ampelorasum</i>	Leek
<i>Allium fistulosum</i>	Scallion
<i>Allium schoenprasum</i>	Chive

Allium Chemistry

The chemistry (and medicine) of alliums has been dominated by the various thiols that contribute most tellingly to the pungency of individual species. These recently reviewed compounds (Fig. 2.1a) provide the pronounced and distinctive odors to onions, garlic and their like.¹ Possibly because of high (olfactory) profile, they have been the subject of much investigation and have been shown to contribute to some of the recognized biology of the crude extracts of the plant material. Thus, compounds such as ajoene and allicin have been widely investigated and shown to be antitumor-promoter², antifungal³, and anti-inflammatory, possibly due to an inhibition of phospholipase.⁴ A second class of compounds that are present in many of these species, the flavonoids (Fig. 2.1b) are well known as antioxidants and anti-inflammatory compounds.⁵ Their presence in some *Allium* species has recently been noted as onions may be the single biggest source of flavonoids in the human diet.⁶

Because of the prominence of the above two groups, it is at first surprising to recognize that saponins are commonly present throughout the genus, since saponins are generally assumed to be associated with toxicity or